Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative Breast Cancer

Published:2023-12-18 Issue:1 Volume:67 Page:479-491
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhang Chen¹,Zhu Jie¹,Yuan Xun¹,Yan Zhengsheng¹,Ye Hui¹^ORCID,Xiong Tao¹,Xu Anning¹,Li Cunrui¹,Ji Duorui¹,Yang Shan²,Zhang Juan³^ORCID,Zhang Yihua¹^ORCID,Wu Jianbing¹^ORCID,Huang Zhangjian¹⁴^ORCID

Affiliation:

1. Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, P. R. China

2. Xinjiang Key Laboratory of Neurological Disorder Research, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi 830028, P. R. China

3. School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, P. R. China

4. School of Pharmacy, Key Laboratory of Active Components of Xinjiang Natural Medicine and Drug Release Technology, Engineering Research Center of Xinjiang and Central Asian Medicine Resources, Xinjiang Medical University, Urumqi 830054, P. R. China

Funder

China Pharmaceutical University

Natural Science Foundation of Xinjiang Uygur Autonomous Region

National Natural Science Foundation of China

Science and Technology Supporting Xinjiang Project

State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01693

Reference41 articles.

1. Triple‑negative breast cancer therapy: Current and future perspectives (Review)

2. Insight into the heterogeneity of breast cancer through next-generation sequencing

3. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

4. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

5. An overview of triple-negative breast cancer